First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $8M — +106% growth in a single year.
What Moves the Stock
1Clinical trial data readouts - particularly overall response rates (ORR), duration of response (DOR), and progression-free survival (PFS) in lead melanoma and NSCLC programs versus historical benchmarks
2FDA regulatory interactions - IND clearances for new indications, Fast Track/Breakthrough Therapy designations, or clinical hold notifications
3Manufacturing platform milestones - Gen2/Gen3 process validation data showing reduced production timelines or improved cell characteristics
4Capital raises and cash runway updates - equity offerings, debt financing, or partnership deals that extend operational runway beyond 12-18 months
5Competitive developments from Iovance Biotherapeutics (primary TIL competitor) including their commercial launch progress and market penetration data
6No current revenue - pre-commercial stage
7Future potential: TIL therapy product sales post-approval (estimated $150K-$400K per patient treatment course based on CAR-T pricing benchmarks)
8Future potential: Partnership/licensing revenue from geographic or indication-specific collaborations
High sensitivity through valuation multiple compression.
Watch on earnings: Quarterly cash burn rate and ending cash balance - signals runway to next financing event, Clinical trial enrollment velocity and data readout timelines for lead programs, Overall response rate (ORR) and duration of response (DOR) in melanoma and NSCLC cohorts versus 30-40% ORR benchmarks.
One Sentence Summary:
Instil Bio: the story is balanced — clinical trial data readouts - particularly overall response rates (orr), duration of response (dor).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.